Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double‐blind, randomized, nonpivotal, exploratory field study

Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double‐blind, randomized, nonpivotal, exploratory field study

Background The benefits of pimobendan in the treatment of congestive heart failure (CHF) in cats with hypertrophic cardiomyopathy (HCM) have not been evaluated prospectively. Hypothesis/Objectives To investigate the effects of pimobendan in cats with HCM and recent CHF and to identify possible endpo...

Full description

Saved in:
Bibliographic Details
Published in:Journal of veterinary internal medicine Vol. 35; no. 2; pp. 789 - 800
Main Authors: Schober, Karsten E., Rush, John E., Luis Fuentes, Virginia, Glaus, Tony, Summerfield, Nuala J., Wright, Kathy, Lehmkuhl, Linda, Wess, Gerhard, Sayer, Margaret P., Loureiro, Joao, MacGregor, John, Mohren, Nicole
Format: Journal Article
Language:English
Published: Hoboken, USA John Wiley & Sons, Inc 01-03-2021
Wiley
Subjects:
Asymptomatic
Blood pressure
Cardiomyopathy
Cats
clinical trial
Double-blind studies
dynamic outflow tract obstruction
Edema
Enrollments
feline
Field study
Heart failure
Hypotheses
Medical prognosis
Morbidity
Pleural effusion
Population
positive inotrope
SMALL ANIMAL
Statistical analysis
Success
survival
Thromboembolism
treatment
United States > US
Europe
clinical trial
treatment
positive inotrope
feline
dynamic outflow tract obstruction
survival
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The benefits of pimobendan in the treatment of congestive heart failure (CHF) in cats with hypertrophic cardiomyopathy (HCM) have not been evaluated prospectively. Hypothesis/Objectives To investigate the effects of pimobendan in cats with HCM and recent CHF and to identify possible endpoints for a pivotal study. We hypothesized that pimobendan would be well‐tolerated and associated with improved outcome. Animals Eighty‐three cats with HCM and recently controlled CHF: 30 with and 53 without left ventricular outflow tract obstruction. Methods Prospective randomized placebo‐controlled double‐blind multicenter nonpivotal field study. Cats received either pimobendan (0.30 mg/kg q12h, n = 43), placebo (n = 39), or no medication (n = 1) together with furosemide (<10 mg/kg/d) with or without clopidogrel. The primary endpoint was a successful outcome (ie, completing the 180‐day study period without a dose escalation of furosemide). Results The proportion of cats in the full analysis set population with a successful outcome was not different between treatment groups (P = .75). For nonobstructive cats, the success rate was 32% in pimobendan‐treated cats versus 18.2% in the placebo group (odds ratio [OR], 2.12; 95% confidence interval [CI], 0.54‐8.34). For obstructive cats, the success rate was 28.6% and 60% in the pimobendan and placebo groups, respectively (OR, 0.27; 95% CI, 0.06‐1.26). No difference was found between treatments for the secondary endpoints of time to furosemide dose escalation or death (P = .89). Results were similar in the per‐protocol sets. Adverse events in both treatment groups were similar. Conclusions and Clinical Importance In this study of cats with HCM and recent CHF, no benefit of pimobendan on 180‐day outcome was identified.
Bibliography:Funding information
Boehringer Ingelheim Vetmedica GmbH
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Undefined-2
Funding information Boehringer Ingelheim Vetmedica GmbH
ISSN:0891-6640
1939-1676
DOI:10.1111/jvim.16054